Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm’s broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.
The firm is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law, among other areas. Our distinguished international roster of clients span a wide variety of industries, including information technology, life sciences, energy and clean technology, media and entertainment, communications, retail, and financial services.
For more information, visit www.wsgr.com.
Suzhou BioBAY is the key driver of life science innovation for Suzhou Industrial Park (SIP). Nearly 500 high-tech innovative companies covering drug discovery, medical device (including IVD), biotech, CRO, and nanotech have been located in BioBAY. 8000 scientists and professionals have come to join this dynamic innovative community, including 60 talents of The Recruitment Program of Global Experts.
BioBAY is playing an active role in building an interactive and collaborative innovation ecosystem:
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.
Founded by industry-recognized editors, RNDer and PharmaDJ are the leading publications providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers.
Since its founding in 2007, ChinaBio® Group has created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped western life science companies identify over 400 licensing and acquisition opportunities and raise over USD 500 million in funding in China.
The 2017 BioCentury China Healthcare Summit is an annual forum to identify the essential next steps to creating a modern healthcare ecosystem in China based on a foundation of scientific, business and policy innovations. This VIP event is organized by BioCentury and BayHelix in collaboration with McKinsey & Co. It is a closed-door meeting limited to senior-level biopharma and medtech executives, investors and academia. The Summit features two days of action-oriented discussion and networking among peers. Attendees will receive an exclusive conference report from McKinsey documenting market trends and identifying business imperatives for China healthcare innovators. For more information, please contact Joshua Berlin at firstname.lastname@example.org or WeChat ID: "joshberlin", or visit our website: www.BioCenturyChinaSummit.com.
BioCentury is the essential source of intelligence for a global audience of biotech and pharmaceutical company professionals, investors, researchers, service providers and industry stakeholders who demand deep industry knowledge, data-driven analysis, independent perspective and a commitment to accuracy. Our insight, trusted reporting and in-depth analysis are built on independent, objective surveillance of the biotechnology sector, producing the industry's most respected journals and data solution resources, since 1993. For more information please visit:www.biocentury.com
Founded in 2002, GBI (www.gbihealth.com) is an information, applications and services company focused on the healthcare industry. It boasts a diverse portfolio of marketing intelligence solutions that enable organizations and individuals to make data-driven decisions and communicate more effectively. Over 15 years of development, GBI has built a global presence with around 200 staff across four locations in Shanghai, Beijing, São Paolo, and Washington, DC. Our first database product was launched in 2009, and we have now built a portfolio based around the flagship brands of SOURCE, DEVINT, METRIX and NAVIS, covering the markets of China, Latin America, and the United States. GBI is now a trusted provider for the pharmaceutical and medtech industries, with established long-term partnerships with multinational industry players. www.gbihealth.com
Lingmed helps pharmaceutical/device industry to improve productivities, make better decisions with intelligence databases. Currently Lingmed is the exclusive partner of EvaluatePharma and Biotechgate in China and GBI Source China’s local market partner. Lingmed databases cover more than 36,000 pharma, medtech and biotech companies, over 45,000 innovative products’ active licensing opportunities. Lingmed databases are the trusted source for life science market intelligence and analysis with exclusive consensus forecasts, which supports life science and healthcare companies in their strategic decision-making. Lingmed also supports oversea innovative assets to enter China market on deal making with local BD professionals.